Oragenics Signs LOI to License CardioDialysis Technology From Sigyn Therapeutics

Oragenics (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) announced the signing of a letter of intent under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn's CardioDialysis blood purification technology for traumatic brain injury and chronic neurodegenerative diseases. This complements Oragenics' Phase IIa intranasal neurosteroid candidate ONP-002 in a proposed dual-modality approach targeting inflammation on both sides of the blood-brain barrier.

The move signals Oragenics' strategic expansion beyond its lead candidate ONP-002, which is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. By adding Sigyn's technology, Oragenics aims to address systemic inflammation outside the brain, while ONP-002 targets inflammation within the brain. This dual approach could enhance treatment efficacy for conditions where inflammation plays a key role, such as traumatic brain injury, Alzheimer's disease, and Parkinson's disease.

Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company recently announced plans to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.

The licensing of CardioDialysis technology represents a significant step in Oragenics' commitment to addressing unmet medical needs in neurological care. Sigyn's blood purification technology is designed to remove a broad spectrum of inflammatory mediators from the blood, which could complement the neurosteroid's mechanism of action. This combination therapy could potentially offer a more comprehensive treatment approach for patients suffering from traumatic brain injury and neurodegenerative diseases.

For more information on Oragenics and its pipeline, visit the company's newsroom at https://ibn.fm/OGEN. The full press release about the LOI is available at https://ibn.fm/VD4RO.